citalopram has been researched along with Muscle Spasticity in 3 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Muscle Spasticity: A form of muscle hypertonia associated with upper MOTOR NEURON DISEASE. Resistance to passive stretch of a spastic muscle results in minimal initial resistance (a free interval) followed by an incremental increase in muscle tone. Tone increases in proportion to the velocity of stretch. Spasticity is usually accompanied by HYPERREFLEXIA and variable degrees of MUSCLE WEAKNESS. (From Adams et al., Principles of Neurology, 6th ed, p54)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Further studies should evaluate whether repeated dosing of SSRIs, or as combined with specific interventions, is required to elicit significant benefit of these agents on lower limb function poststroke." | 2.80 | Increased Lower Limb Spasticity but Not Strength or Function Following a Single-Dose Serotonin Reuptake Inhibitor in Chronic Stroke. ( Gourab, K; Hornby, TG; Schmit, BD, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ryu, Y | 1 |
| Ogata, T | 1 |
| Nagao, M | 1 |
| Sawada, Y | 1 |
| Nishimura, R | 1 |
| Fujita, N | 1 |
| Gourab, K | 1 |
| Schmit, BD | 1 |
| Hornby, TG | 1 |
| D'Amico, JM | 1 |
| Murray, KC | 1 |
| Li, Y | 1 |
| Chan, KM | 1 |
| Finlay, MG | 1 |
| Bennett, DJ | 1 |
| Gorassini, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Enhanced Motor Recovery Using Serotonergic Agents in Stroke[NCT01751854] | Phase 1 | 30 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for citalopram and Muscle Spasticity
| Article | Year |
|---|---|
Increased Lower Limb Spasticity but Not Strength or Function Following a Single-Dose Serotonin Reuptake Inhibitor in Chronic Stroke.
Topics: Aged; Ankle; Chronic Disease; Citalopram; Cross-Over Studies; Double-Blind Method; Female; Hemiplegi | 2015 |
2 other studies available for citalopram and Muscle Spasticity
| Article | Year |
|---|---|
Early escitalopram administration as a preemptive treatment strategy against spasticity after contusive spinal cord injury in rats.
Topics: Animals; Citalopram; Female; Muscle Spasticity; Rats; Rats, Sprague-Dawley; Selective Serotonin Reup | 2021 |
Constitutively active 5-HT2/α1 receptors facilitate muscle spasms after human spinal cord injury.
Topics: Action Potentials; Adult; Aged; Biogenic Monoamines; Calcium; Case-Control Studies; Chlorpromazine; | 2013 |